6th Annual MarketsandMarkets

Next-Gen Immuno-Oncology Conference

22nd -23rd June 2023

Hilton Boston Logan Airport

Our 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, at Hilton Boston Logan Airport, Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

CO-LOCATED CONFERENCES

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

New Antibody Formats & Cellular Therapy

Keynote: Immuno-oncology Continues to Transform Oncology Therapeutics

Roy Baynes

Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics

09:00 - 09:30

Validated FOXP3 methylation panel to profile culture-induced epigenetic changes at Treg-specific loci

Sarah Miller

Sarah Miller, Senior Research Associate, EpigenDx

09:30 - 10:00

Evaluating Efficacy of Novel Antibody and Cell-Based Therapeutics with Next-Generation Mouse Models

Jenna Frame

Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

Challenges and Opportunities for Immuno-oncology (IO) and Antibody Drug Conjugates (ADC) Therapeutics To Treat Cancers

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

11:15 - 11:45

Veracyte Biopharma Atlas, a comprehensive cancer reference database

Peter Russo

Peter Russo, Director, Business Development, Biopharma, Veracyte

11:45 - 12:15

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

12:15 - 12:45

Lunch and Poster Presentations | One-to-One Networking Meetings

12:45 - 13:45

Deciphering the role of natural killer cells in breast cancer

Isaac Chan

Isaac Chan, Assistant Professor, UT Southwestern

13:45 - 14:15

Sanyou Biopharmaceuticals - Global leading integrated R&D service platforms for innovative biologics research

Jin Qiu

Jin Qiu, Director, Business Development, Sanyou Bio

14:15 - 14:45

Search for “right” molecule and “right” dose: Case Studies from immuno-oncology portfolio

Ayse Meric Ovacik

Ayse Meric Ovacik, Senior Principal Scientist, Genentech

14:45 - 15:15

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:15 - 16:00

Targeted mRNA for in vivo Reprogrammed off-the-shelf CAR-T Therapies

Dharini Shah

Dharini Shah, Senior Research Director, Immunology, Sanofi

16:00 - 16:30

SpliceIO- a robust platform for the discovery and validation of Splicing- derived neoantigens

Gayatri Arun

Gayatri Arun, Vice President, Envisagenics

16:30 - 17:00

Evaluating clinical and pharmacodynamic data of CLL patients treated with ibrutinib and an ADCC- enhanced anti-BAFF-R antibody (VAY736)

 Nadia Hassounah

Nadia Hassounah, Principal Scientist, Novartis

17:00 - 17:30

Closing remarks from the Chairman

17:30 - 17:30

End of Day 1 followed by Drinks Reception and Networking

17:30 - 17:30

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

Alem Truneh

Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics

08:55 - 09:00

New Immune Checkpoints, Biomarker and Tumour Microenvironment

Targeting Immune Stimulants to Myeloid Cells For Cancer Immunotherapy

Christopher Garris

Christopher Garris, Assistant Professor, Massachusetts General Hospital, Harvard Medical School

09:00 - 09:30

Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure

Alexander Bagaev

Alexander Bagaev, Vice President, Product Development, BostonGene

09:30 - 10:00

Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine

Matt Davis

Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

How humanized mice reinforce your preclinical immuno-oncology research

Dan Georgess

Dan Georgess, Chief Scientific Officer, TransCure bioServices,

11:15 - 11:45

T-cell Receptor Profiling from low input RNA Samples using NGS

Jonathan Shaffer

Jonathan Shaffer, Director, R&D, Qiagen

11:45 - 12:15

Turning preclinical findings into clinic-ready biomarker assays to support the phase I/II of BT7480, a Bicycle tumor-targeted immune cell agonist®

Heather Cohen

Heather Cohen, Director, Translational Sciences, Bicycle Therapeutics

12:15 - 12:45

Lunch and Poster Presentation | One-to-One Networking Meetings

12:45 - 13:45

Next generation checkpoints beyond PD-1 and CTLA-4

Nindhana Paranthaman

Nindhana Paranthaman, Principal Medical Director Oncology, Genentech

13:45 - 14:15

Targeting Beta-Cantenin reprograms the tumor microenvironment & stimulates a robust anti-tumor immune response

Bradlee Heckmann

Bradlee Heckmann, Co-Founder, CSO, Asha Therapeutics

14:15 - 14:45

Oncolytic herpes simplex virus immunovirotherapy

Samuel Rabkin

Samuel Rabkin, Professor, Harvard Medical School

14:45 - 15:15

Closing remarks from the Chairman

Alem Truneh

Alem Truneh, Co-founder & Chief Technology Officer, ImCheck Therapeutics

15:15 - 15:15

End of Conference

15:15 - 15:15

SPEAKERS

Roy Baynes

Roy Baynes

Executive Vice President, Chief Medical Officer, Eikon Therapeutics

Jenna Frame

Jenna Frame

Senior Scientist, Scientific Communications, Biocytogen

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Jonathan Shaffer

Jonathan Shaffer

Director, R&D, Qiagen

Peter Russo

Peter Russo

Director, Business Development, Biopharma, Veracyte

Sarah Miller

Sarah Miller

Senior Research Associate, EpigenDx

Jin Qiu

Jin Qiu

Director, Business Development, Sanyou Bio

Heather Cohen

Heather Cohen

Director, Translational Sciences, Bicycle Therapeutics

Matt Davis

Matt Davis

Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

Ayse Meric Ovacik

Ayse Meric Ovacik

Senior Principal Scientist, Genentech

Nindhana Paranthaman

Nindhana Paranthaman

Principal Medical Director Oncology, Genentech

Rakesh Dixit

Rakesh Dixit

CEO, Bionavigen

 Nadia Hassounah

Nadia Hassounah

Principal Scientist, Novartis

Bradlee Heckmann

Bradlee Heckmann

Co-Founder, CSO, Asha Therapeutics

Christopher Garris

Christopher Garris

Assistant Professor, Massachusetts General Hospital, Harvard Medical School

Isaac Chan

Isaac Chan

Assistant Professor, UT Southwestern

Alexander Bagaev

Alexander Bagaev

Vice President, Product Development, BostonGene

Gayatri Arun

Gayatri Arun

Vice President, Envisagenics

Samuel Rabkin

Samuel Rabkin

Professor, Harvard Medical School

Dharini Shah

Dharini Shah

Senior Research Director, Immunology, Sanofi

Dan Georgess

Dan Georgess

Chief Scientific Officer, TransCure bioServices,

ENQUIRE NOW

SPONSORS

Sanyou Bio
Proteome Sciences
Larvol
EpigenDx
Veracyte
BIOCYTOGEN
BostonGene
TransCure bioServices
QIAGEN
Q2 Solutions
Cureline
Biointron
StackWave
HTG Molecular Diagnostics, Inc.
Concept Lifesciences
Detai Bioscience
Talem Therapeutics

PARTNERS

LOCATION

Venue

Hilton Boston Logan Airport

PAST EVENT GALLERY